Irritable bowel syndrome affects approximately 1015% of the global population, and many of those individuals also struggle with weight management
To date, because of the lack of clear consensus and/or evidence-based guidelines, there is a high degree of variability in the diagnostic approach as well as clinical management of these patients [19]
The study was approved by the Local Ethics Committee at School of Medicine (University of Zagreb, Zagreb, Croatia) and experiments were assessed by observers unaware of the given treatment
Phase 3 clinical trials, which test new treatments in larger groups of people, are particularly crucial in ensuring that a drug works as intended and has minimal side effects
[Translated from marnys.es] Thx Good product
As a coach that works closely with GLP-1 users, I will say that I agree with Bharam - without the proper attention we will see negative results